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The coronavirus (CoV) N protein oligomerizes via its carboxyl terminus. However, the oligomeriza-
tion mechanism of the C-terminal domains (CTD) of CoV N proteins remains unclear. Based on the
protein disorder prediction system, a comprehensive series of HCoV-229E N protein mutants with
truncated CTD was generated and systematically investigated by biophysical and biochemical anal-
yses to clarify the role of the C-terminal tail of the HCoV-229E N protein in oligomerization. These
results indicate that the last C-terminal tail plays an important role in dimer–dimer association.
The C-terminal tail peptide is able to interfere with the oligomerization of the CTD of HCoV-229E
N protein and performs the inhibitory effect on viral titre of HCoV-229E. This study may assist the
development of anti-viral drugs against HCoV.
Structured summary of protein interactions:
N and C-terminal tail peptide bind by cosedimentation in solution (View interaction)
N and N bind by cosedimentation in solution (View Interaction: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)
C-terminal tail peptide and N bind by ﬂuorescence technology (View interaction)
N and N bind by cross-linking study (View interaction)
N and N bind by cross-linking study (View Interaction: 1, 2, 3, 4)
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society. All rights reserved.1. Introduction [1,3,4]. There have also been reports that clusters of HCoV-229EHuman coronavirus 229E (HCoV-229E), belonging to the alpha-
coronaviruses, was ﬁrst identiﬁed in the 1960s and has generally
been associated with symptoms of the common cold [1,2].
Although HCoV-229E infections are generally mild, more severe
upper and lower respiratory tract infections, such as bronchiolitis
and pneumonia, have been well documented, particularly in in-
fants, elderly individuals, and immunocompromised patientsinfections cause pneumonia in otherwise healthy adults [2,5]. Sev-
eral emerging human coronaviruses have recently been discovered
[6–8]. Between 2003 and 2004, the severe acute respiratory syn-
drome (SARS)–CoV caused a worldwide epidemic and had a signif-
icant economic impact in the countries where the disease outbreak
occurred [8]. Phylogenetic analyses have shown that SARS–CoV is
closely related to the sequences of the betacoronaviruses [9]. In
2004, another alphacoronavirus (HCoV-NL63) was isolated from a
7-month-old child in the Netherlands suffering from bronchiolitis
and conjunctivitis [7]. In 2005, Woo et al. described the discovery
of a novel betacoronavirus, HKU1, which was found in patients
with respiratory tract infections [10].
CoV particles have an irregular shape that consists of an outer
envelope with distinctive, ‘club-shaped’ peplomers, giving the
virus a crown (corona) appearance [11]. The viral genome of coro-
naviruses consists of positive-sense, single-stranded RNA of
approximately 30 kb, and it contains several genes encoding
Fig. 1. The order/disorder prediction for the full-length HCoV-229E N protein using
the PrDOS program corresponding to the designations of the truncations, including
N245–350, N245–370, N245–376, N245–382 and N245–389. PrDOS scores above a
threshold value of 0.5 denote the disordered regions.
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progeny virion production [1]. The virion envelope surrounding the
nucleocapsid contains the following structural proteins: S (spike)
protein, M (membrane), E (envelope), and N (nucleocapsid). Some
variants have a third glycoprotein, HE (hemagglutinin-esterase),
which is present in most betacoronaviruses [12,13]. A helical
nucleocapsid exists in the center of the viral particle [14–16].
Nucleocapsid protein, the major structural protein of CoVs, binds
the viral RNA genome to form the virion core, leading to the forma-
tion of a ribonucleoprotein (RNP) complex or to a long helical
nucleocapsid structure [17,18]. The formation of the RNP is impor-
tant for maintaining the RNA in an ordered conformation suitable
for replication and transcription of the viral genome [17,19–21].
Previous studies have shown that the CoV N protein is involved
in the regulation of cellular processes, such as gene transcription,
actin reorganization, host cell cycle progression, and apoptosis
[22–25]. The CoV N protein has also been shown to act as an
RNA chaperone [26]. Moreover, the N protein is an important diag-
nostic marker and immunodominant antigen in host immune re-
sponses [21,27,28].
The N protein of HCoV-229E, which has a molecular weight of
50 kDa, is highly basic (pI, 10.0), and it shows strong hydrophilicity
[29]. The HCoV-229E N protein has 26–30% sequence homology
with CoV N proteins from other strains or viruses, such as HCoV-
OC43 and SARS [30]. Despite their low sequence homology, CoV
N proteins from different strains can show a high level of conserva-
tion in some motifs [30]. Chang et al. reported results from an or-
der–disorder prediction and secondary structure prediction
coupled with sequence alignment, which suggested that all CoV N
proteins share the same modular organization [31]. Self-association
of the N protein is an important step in virus particle assembly for
many CoVs [32]. Previous studies have shown that full-length CoV
N proteins can form high-order oligomers, and the C-terminal do-
mains of the CoV N proteins are responsible for oligomerization
[30,33–38]. Crystal structures of the C-terminal domains of CoV N
proteins have been published and suggest that the basic building
block for coronavirus nucleocapsid formation is the dimeric assem-
bly of the N protein [34,39–41]. Luo et al. revealed that the CoV N
protein might combine with viral genomic RNA to generate high-
er-order oligomers, which could trigger the formation of the long
nucleocapsid structure [32]. However, the oligomerization mecha-
nism of the C-terminal domain of the HCoV-229E N protein remains
unclear. The C-terminal tail has been found to participate in the
oligomerization of the SARS–CoV N protein since the removal of
40 aa from the C-terminus apparently decreased the ability of the
protein to oligomerize [32]. The extreme C-terminal tail of the
HCoV N protein was labeled as a separate functional domain [42].
We speculate that the C-terminal tail might constitute an important
molecular determinant of oligomerization for HCoV-229E NP. How-
ever, the recombinant full-length nucleocapsid N protein of the
coronavirus is highly sensitive to proteolysis and aggregation that
is difﬁcult to analyze its oligomerization properties [21]. A compre-
hensive series of HCoV-229E N protein mutants with truncated C-
terminal domains was generated based on the PrDOS prediction
to clarify the role of the C-terminal tail of the HCoV-229E N protein
in oligomerization (Fig. 1). According to the order–disorder proﬁles
obtained from the protein disorder prediction system (PrDOS), the
predicted structure of HCoV-229 N protein contains one long or-
dered region (N245–350) located in the C-terminal domain fol-
lowed by three short regions predicted to be disordered (N351–
370), ordered (N371–382), and disordered (N383–389) (Fig. 1)
[30]. These truncations were systematically investigated by various
biophysical and biochemical analyses. Understanding this mecha-
nism would provide insight into the viral assembly process and
could identify additional targets for drugs to combat CoVs through
the disruption of N protein self-association.2. Materials and methods
The drugs and reagents were purchased from Sigma Chemical
Co. All of oligoribonucleotides (or oligodeoxyribonucleotides) were
synthesized using an automated DNA synthesizer and were puri-
ﬁed by gel electrophoresis.
2.1. Expression and puriﬁcation of the full-length and truncated N
proteins
The templates for the HCoV-229E N protein were kindly pro-
vided by the Institute of Biological Chemistry, Academia Sinica
(Taipei, Taiwan). To generate the truncated forms of the recombi-
nant N proteins, the N protein gene was ampliﬁed by polymerase
chain reaction (PCR) from the plasmid pGENT using various prim-
ers. The PCR products were digested with NdeI and XhoI, and the
DNA fragments were cloned into pET21b (Novagen) using T4 ligase
(NEB). The induction of protein expression was initiated by adding
IPTG to 1 mM followed by incubation at 37 C for 6 h. After har-
vesting the bacteria by centrifugation (6000 rpm, 30 min, 4 C),
the bacterial cells were lysed with lysis buffer (50 mM Tris–HCl,
pH 7.3, 150 mM NaCl, and 15 mM imidazole). The lysate was clar-
iﬁed by centrifugation (15,000 rpm, 30 min, 4 C) to obtain soluble
proteins. The truncated C-terminal domains of the N protein with
an C-terminal His6-tag were puriﬁed using a Ni–NTA column
(Novagen) with an elution gradient from 15 to 250 mM imidazole
in the buffer solution. The fractions containing the target proteins
were collected and dialyzed against a low-salt buffer.
2.2. Circular dichroism (CD) spectroscopy
The CD spectra were obtained using a JASCO-815 CD spectropo-
larimeter. The temperature was controlled by circulating water at
the desired temperature in the cell jacket. Each protein was dis-
solved in 50 mM Tris–HCl, pH 7.3, and 150 mM NaCl. The CD spec-
tra were collected between 250 and 190 nm with a 1 nm
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an average of ﬁve scans. The photomultiplier absorbance did not
exceed 600 V during the analysis. The CD spectra were normalized
by subtraction of a background scan with buffer alone. The mean
residue ellipticity, [h], was calculated based on the equation
[h] = MRW  hk/10  l  c, where MRW is the mean residue weight,
hk is the measured ellipticity in millidegrees at wavelength k, l is
the cuvette path length (0.1 cm), and c is the protein concentration
in g/ml. The results were analyzed using the CDSSTR program to
calculate the percentage of each type of secondary structure [43].
In addition, the Tm was determined from the polynomial ﬁtting
of the observed curve and taken as the temperature corresponding
to half denaturation of the N protein. The ﬁrst derivative of the
absorption with respect to temperature, dA/dT, of the melting
curve was computer generated and used to determine the Tm.
2.3. Chemical crosslinking assay
To investigate the oligomerization features of N proteins, a
chemical crosslinking experiment was performed. A series of pro-
tein solutions containing N proteins were supplemented with var-
ious concentrations of glutaraldehyde, and the reaction mixture
was incubated at room temperature for 5 min. The reaction was
stopped by adding 1 M Tris–HCl at pH 7.3 (0.5%, v/v, ﬁnal concen-
tration) and placing it on ice. The sample was then analyzed by
SDS–PAGE.
2.4. Fluorescence spectroscopy
In the peptide-induced ﬂuorescence quenching experiments, a
ﬁnal concentration of 5 lM N protein was added to a buffer that
contained various concentrations of peptide, and the samples were
incubated at 25 C for various durations. The buffer consisted of
50 mM Tris–HCl (pH 7.5) and 150 mM NaCl. The tryptophan ﬂuo-
rescence was measured using a Hitachi F-4500 ﬂuorescence spec-
trophotometer that was equipped with a cuvette of a 1 cm light
path. The excitation wavelength was 288 nm, and the emission
data were collected between 300 and 400 nm. For the static mea-
surements, all of the measurements were recorded in triplicate.
To determine the binding constant between the peptide and the
N proteins, the peptide-induced ﬂuorescence changes (DF) from
three separate experiments at 1 h after the addition of the test pep-
tide were averaged and ﬁt with the Hill equation using the Graph-
Pad Prism software program (San Diego, CA) as follows: DF/
DFmax = 1/[1 + (Kd/X)n], where DFmax is the saturating value of the
ﬂuorescence change, X is the drug concentration, Kd is the dissoci-
ation constant, and n is the Hill coefﬁcient [44].
2.5. Size-distribution analysis by analytical ultracentrifugation
Sedimentation velocity experiments were performed using a
Beckman Optima XL-A analytical ultracentrifuge. The sample solu-
tions (380 ll) and the buffer solutions (400 ll) were loaded into
the double-sector centerpiece separately and built up in a Beckman
An-50 Ti rotor. The experiments were performed at 20 C with a ro-
tor speed of 42,000 rpm. The protein samples were monitored by
measuring the UV absorbance at 280 nm in continuous mode with
a time interval of 420 s and a step size of 0.002 cm. Multiple scans
at different time points were ﬁt to a continuous size distribution
model using the program SEDFIT [45] (Fig. S1). All of the size dis-
tributions were solved at a conﬁdence level of P = 0.95, a best-ﬁt
average anhydrous frictional ratio (f/f0), and a resolution N of 250
sedimentation coefﬁcients between 0.1 and 20.0 S. To precisely
determine the dimer–tetramer dissociation constants (Kd,24) of
the C-terminal domains of the HCoV-229E N proteins in dimer–tet-
ramer–oligomer equilibrium, sedimentation velocity experimentswere performed for three different protein concentrations. The di-
mer–tetramer dissociation constant (Kd,24) of the C-terminal domains
of the HCoV-229E N proteins was analyzed using the SEDPHAT pro-
gram with a monomer-m-mer-n-mer self-association model [46].
The sedimentation velocity data collected for three different protein
concentrations were globally ﬁt with SEDPHAT. The solvent density
and viscosity were calculated by the SEDNTERP program (Philo,
J. website http://www.jphilo.mailway.com/default.htm).
3. Results
3.1. Oligomerization characterization of the HCoV-229E nucleocapsid
protein C-terminus
The C-terminal region of the HCoV N protein has been shown to
mediate the self-association of the protein. The self-association
mechanism of the full-length HCoV-229E N protein has been pre-
viously reported [21,47]. To determine whether the C-terminal tail
region (N351–389) plays an important role in the oligomerization
of the C-terminal domain of the HCoV-229E N protein, the oligo-
merization of several regions of the C-terminal domain of the N
protein were analyzed using analytical ultracentrifugation. The dif-
ferences in the size distributions among these truncated N proteins
were analyzed by sedimentation velocity experiments, and the di-
mer–tetramer dissociation constant (Kd,24) for each was deter-
mined. The dimer–tetramer dissociation constant (Kd,24) reﬂects
the afﬁnity between two N protein dimers, with smaller numbers
representing a higher tendency to oligomerize into tetramers.
The truncated N245–350 protein predominantly displays a dimeric
quaternary structure with a small amount of tetramers (Fig. 2A),
exhibiting a Kd,24 value of 256 lM. With an extended C-terminal
tail that includes residue 370 or residue 376, the respective trun-
cated N245–370 and N245–376 proteins also exist as dimers in
solution with the major peaks exhibiting Kd,24 values of 177 and
159 lM, respectively (Fig. 2B and C). With an extended C-terminal
tail that includes residue 382 or residue 389, the respective trun-
cated N245–382 and N245–389 proteins demonstrated signiﬁcant
shifts in the equilibrium from dimers to tetramers and octamers,
with signiﬁcant decreases in the Kd,24 values (3.83 and 3.50 lM,
respectively) (Fig. 3A and B). These results indicate that residues
377–389 at the end of the C terminus are necessary for the oligo-
merization of the HCoV-229 N protein.
3.2. Conformational and stability studies of the HCoV-229E
nucleocapsid protein C terminus
The conformation of the truncated C-terminal domain of the
HCoV-229E N protein, including N245–350, N245–370, N245–
376, N245–382, and N245–389, were monitored using CD spec-
troscopy. As shown in Fig. 4A, the CD spectra of these truncated
C-terminal domains of the HCoV-229E N protein were scanned
from 190 to 250 nm at 25 C. The CD spectrum of N245–350
showed well-structured domains with a-helical and b-sheet sec-
ondary structures as well as two negative peaks at approximately
205 and 220 nm, respectively. The CD spectra of N245–370,
N245–376, N245–382, and N245–389, which contain extended C-
terminal tails, showed increased intensities at approximately 205
and 220 nm, suggesting that they possessed a different secondary
structure composition compared to N245–350. These CD spectra
were further analyzed by the CDPro software to determine the
quantitative percentages of the secondary structure (Table 1).
N245–350 contains approximately 51% a-helices, 22% b-sheets,
12% turns, and 15% random coils at 25 C. With an extended C-ter-
minal tail that includes residue 370, N245–370 showed a signiﬁ-
cant increase in undeﬁned structural content with 14% turns and
17% random coils, consistent with the PrDOS prediction indicating
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Fig. 2. The continuous sedimentation coefﬁcient distributions of the different
HCoV-229E N protein truncations (A) N245–350, (B) N245–370, and (C) N245–376.
The protein concentrations were 50, 30 and 10 lM. The buffer consisted of 50 mM
Tris–HCl (pH 7.5), 150 mM NaCl and 0.1% b-mercaptoethanol. Dimer and tetramer
are denoted as D and T.
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N245–350, N245–370, and N245–376, N245–382 and N245–389
showed signiﬁcant increases in the b-sheet content because they
may contain an ordered region in their C-terminal tail as predicted
by the PrDOS prediction.
We also measured the melting temperatures (Tms) of the trun-
cated C-terminal domains of the HCoV-229E N protein, includingN245–350, N245–370, N245–376, N245–382, and N245–389,
using CD in which the absorbance at 220 nm was analyzed as a
function of temperature (Fig. 4B). The heat denaturation analysis
showed that the Tms of N245–350, N245–370, and N245–376 were
almost identical with values of 35.5, 36.2, and 36.7 C, respectively.
Interestingly, the Tms of N245–382 and N245–389, with values
above 70 C, were greater than N245–350, N245–370, and N245–
376, indicating that oligomerization contributes signiﬁcantly to
the stability of the C-terminal domain of the N protein. The melting
temperatures (Tms) of the truncated C-terminal domains of the
HCoV-229E N protein from CD studies were further conﬁrmed by
tryptophan (Trp) ﬂuorescence analyses (Table S1).
3.3. Interference of the oligomerization of the HCoV-229E nucleocapsid
protein C terminus by a C-terminal tail peptide
A previous observation indicated that a deletion mutant of the
HCoV-229E N protein C-terminal domain lacking 13 amino acids
from the C-terminal tail appeared incapable of a high degree of
oligomerization. To explore whether a C-terminal tail peptide (res-
idues 377–389) can compete with the oligomerization site of the
C-terminal domain of the HCoV-229E N protein and interfere with
its oligomerization, we synthesized a C-terminal tail peptide
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Fig. 4. (A) The CD spectra of the HCoV-229E N protein truncations N245–350,
N245–370, N245–376, N245–382 and N245–389. The protein concentration was
5 lM, and the buffer consisted of 50 mM Tris–HCl (pH 7.5), 150 mM NaCl and 0.1%
b-mercaptoethanol. (B) The thermostability measurements of N245–350, N245–
370, N245–376, N245–382 and N245–389 monitored by CD at 220 nm. The protein
concentration was 7 lM, and the buffer consisted of 50 mM Tris–HCl (pH 7.5),
150 mM NaCl and 0.1% b-mercaptoethanol.
Table 1
The secondary structural content (%) of the truncated C-terminal domain of the HCoV-
229E N protein as determined by CD analysis.
Construct Helix Sheet Turn Disordered NRMSD
N245–350 51a 22 12 15 0.118
N245–370 46 23 14 17 0.080
N245–376 47 22 16 15 0.124
N245–382 43 25 19 13 0.089
N245–389 45 26 16 13 0.098
a This value was determined by the CDSSTR program.
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Fig. 5. (A) The ﬂuorescence spectra of N245–389 in Tris–HCl buffer with different
concentrations of N377–389 peptide. The protein concentration was 5 lM, and the
buffer consisted of 50 mM Tris–HCl (pH 7.3), 150 mM NaCl and 0.1% b-mercap-
toethanol. (B) Titration of the N245–389 protein with the N377–389 peptide in
50 mM Tris (pH 7.5), 150 mM NaCl and 0.1% b-mercaptoethanol. The average of
three experiments is shown. The data are expressed as a percentage of the maximal
ﬂuorescence change as determined by a ﬁt to the Hill equation.
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this C-terminal tail peptide. First, we utilized ﬂuorescence to mon-
itor the protein/peptide binding because N245–389 contains one
tryptophan residue, which contributes to its intrinsic ﬂuorescence.
The ﬂuorescence emission spectra for N245–389 showed the max-
imal emission wavelength at approximately 332 nm with a ﬂuo-
rescence intensity of 142.4 AU (Fig. 5A). At the C-terminal tail
peptide concentrations of 5, 10, 20, 50, 75 and 100 lM, the C-ter-
minal tail peptide decreased the ﬂuorescence intensity of N245–389 at approximately 332 nm by 8.7, 19, 23.5, 25.4, 26.9 and
28.9 AU, respectively, after 4 h of peptide addition. The N245–
389 ﬂuorescence decreased with increasing concentrations of the
C-terminal tail peptide, which suggests that this decrease reﬂected
the interaction of N245–389 with the C-terminal tail peptide. As
shown in Fig. 5B, the ﬂuorescence quenching of N245–389 by the
C-terminal tail peptide was analyzed with a Hill plot after the addi-
tion of the peptide. The dissociation constant of the C-terminal tail
peptide for N245–389 was calculated to be 7.43 lM.
To quantify the effect of the C-terminal tail peptide on the di-
mer–dimer association for N245–389, the dimer–tetramer dissoci-
ation constant (Kd,24) for the N245–389 protein was determined in
the absence and presence of the C-terminal tail peptide. Sedimenta-
tion velocity (SV) experiments with increasing concentrations of
the C-terminal tail peptide were performed, and the data were
globally ﬁt to determine the dimer–tetramer dissociation constant
of N245–389. Fig. 6 shows the distribution plots of the N245–389
protein in the absence and presence of the C-terminal tail peptide.
In the absence of the C-terminal tail peptide, N245–389 formed a
stable dimer, tetramer, and octamerwith S-values of approximately
2.85, 5.30 and 7.75, respectively, corresponding to the molecular
masses of 31, 69, and 131 kDa, respectively. When the concentra-
tions of the C-terminal tail peptide were increased, the N245–389
tetramer and octamer peak decreased, whereas the N245–389
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30 lM with two concentrations of the C-terminal tail peptide, N377–389, at 120
and 300 lM. The buffer consisted of 50 mM Tris–HCl (pH 7.5), 150 mM NaCl and
0.1% b-mercaptoethanol. Dimer, tetramer, and octamer are denoted as D, T, and O.
Fig. 7. A schematic mechanism of tetramer formation by the N protein showing
that the N proteins form a tetramer through the interactions between the C-
terminal tails of the dimer.
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N377–389 was 0.25 and 0.1, the Kd,24 value for N245–389 was
approximately 6.1 and 9.7 lM, respectively, and it is signiﬁcantly
higher than that of N245–389 in the absence of the C-terminal tail
peptide. These results indicate that the N245–389 tetramer and
octamer was signiﬁcantly dissociated into dimers in the presence
of the peptide (N377–389) and suggest that the C-terminal tail
peptide may complete the tetramer interface of N245–389 and
interfere with the oligomerization of N245–389. We further
analyze the effects of the peptide, N377–389, on the cell viability
and viral titre of HCoV-229E. The results showed that the cell viabil-
ity was not affected by treatment with N377–389 alone (300 lM)
for 24 h in A549 cell lines (Fig. S2A). In addition, viral titre of
HCoV-229E was inhibited by N377–389 at 300 lM, signiﬁcantly
(Fig. S2B).
4. Discussion
The C-terminal domains of the SARS–CoV and HCoV-OC43 N
proteins mediate the self-association of the protein to form high-
order oligomers. These oligomers exist predominantly as dimers
[47,48]. The secondary structure alignment of the C-terminal do-
mains from the HCoV-229E N protein with the corresponding pro-
teins from SARS–CoV and IBV indicates that these proteins share
very similar secondary structure proﬁles [49]. The crystal struc-
tures of the C-terminal domains of SARS–CoV, IBV, and MHV N pro-
teins show a similar general polypeptide fold, which strongly
suggests that the dimerized N protein is the functional unit
in vivo for the four groups of coronaviruses [35,39]. The crystal
structure of the C-terminal domain shows a tightly intertwined
twofold symmetric C-terminal domain dimer, with a b-hairpin
(b1 and b2) from one subunit extending into the cavity of the
opposite subunit, which forms an antiparallel b-sheet with hydro-
gen bonds occurring across the dimer interface [39]. Chang et al.
proposed that all coronaviruses employ the same interface mecha-
nism for the dimerization of the N protein [48]. Based on the crys-
tal structures of the N proteins from SARS–CoV, MHV, and IBV, the
dimeric C-terminal structural domain of the HCoV-229E N protein
has been mapped to N245–350. Here, analytical ultracentrifuga-
tion analysis consistently shows that the dimer appears to be the
functional unit for the C-terminal domain of the HCoV-229E N pro-
tein. The dimeric N245–350 self-associates into a small amount of
tetramers. A crosslinking assay was also conducted to investigateoligomerization by the C-terminal domain of the N protein. As
shown in Fig. S3A, the crosslinking studies of N245–350 also de-
tected dimers and tetramers.
The dimeric C-terminal structural domain of the HCoV-229E N
protein (N245–350) is capped by the C-terminal tail (N351–389).
Compared to N245–350, the crosslinking results showed that
N245–389 forms dimers and tetramers as well as high-order olig-
omers (Fig. S3B). The analytical ultracentrifugation results were
consistent with that of the chemical crosslinking analysis. Our re-
sults demonstrate that the C-terminal tail plays a crucial role in N
protein oligomerization. According to the PrDOS prediction, the C-
terminal tail (N351–389) is composed of disordered (N351–370),
ordered (N371–382), and disordered (N383–389) regions. The
truncations of the C-terminal domain of the HCoV-229E N protein,
N245–370 and N245–376, which contain the ﬁrst disordered re-
gion of the C-terminal tail display a predominantly dimeric quater-
nary structure with a small amount of tetramers and high-order
oligomers and exhibit Kd,24 values of 177 and 159 lM, respectively.
Interestingly, when the dimeric C-terminal structural domain of
the HCoV-229E N protein includes the C-terminal tail to either
residue 382 or 389, containing the short ordered region, the
respective proteins, N245–382 and N245–389, demonstrated equi-
librium shifts toward tetramers and octamers, indicating that the
last 13 residues of the C-terminal tail may play an important role
in dimer–dimer association. A computer-assisted prediction of
the secondary structure based on the amino acid sequence pre-
dicted a short b-strand at the end of the C-terminal tail (Fig. S4),
which is consistent with the CD results that showed that N245–
382 and N245–389 contain higher b-sheet content compared to
the other C-terminal domain truncations of the HCoV-229E N pro-
tein. Therefore, we speculate that the hydrogen bonds across the
tetramer interface formed by the main chain atoms of the short
126 Y.-S. Lo et al. / FEBS Letters 587 (2013) 120–127b-strand may stabilize the oligomerization of the C-terminal do-
main of the N protein through domain-swapping (Fig. 7).
Oligomerization usually occurs through interfacial interactions
in which subunits cooperatively interact with each other in several
ways, including domain swapping and coiled–coil interaction [50].
Previous studies have shown that oligomerization makes a crucial
contribution to the stability of proteins [51]. Many archaeal pro-
teins have homo-oligomeric structures, and some reports have
shown a correlation between oligomerization and the hyperther-
mostability of archaeal proteins [52]. In this report, N245–382
and N245–389 show a very high degree of stability compared to
the other C-terminal domain truncations of the HCoV-229E N pro-
tein due to a high degree of subunit interactions. The inhibition of
viral N protein oligomerization by developing competing peptides
and small organic compounds is an attractive therapeutic strategy
against viral infection [53–55]. We showed that a peptide based on
the C-terminal tail interfered with the oligomerization of the C-ter-
minal domain of the HCoV-229E N protein, N245–389 and per-
formed the inhibitory effect on viral titre of HCoV-229E. These
results suggest that small molecules or peptides could be designed
to target the oligomer interface as potential inhibitors of the CoV.
An amino acid sequence alignment of the C-terminal domains
from the HCoV-229E N protein and corresponding proteins from
SARS–CoV, IBV and HCoV-OC43 using the MultAlin program re-
veals low sequence homology in the C-terminal tail (Fig. S5) [49].
However, they share similar order–disorder proﬁles in the C-termi-
nal domain according to the PrDOS prediction (Fig. S6), suggesting
that the oligomerization feature described above may be conserved
across different groups of Coronaviridae. This study may assist the
development of drugs to disrupt the oligomerization of the viral N
protein and viral assembly.
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